Patent Term Extension and Compensation in China for Foreign Pharmaceutical Companies
๐
2026-06-01
๐ท๏ธ Patent
## Patent Term Extension and Compensation in China: A Practical Guide for Foreign Pharmaceutical Companies
As the world's second-largest pharmaceutical market, China's patent system has a decisive impact on the business strategies of foreign pharmaceutical companies. The fourth amendment to the Patent Law, effective June 1, 2021, introduced the Patent Term Extension (PTE) system, designed to compensate for the actual loss of patent term caused by delays in marketing approval. This system is of great significance to innovative pharmaceutical companies, especially foreign enterprises that rely on patent protection to recoup R&D investments. This article provides a comprehensive practical guide from five dimensions: legal framework, applicable conditions, calculation rules, application procedures, and risk control.
### Institutional Background and Legal Basis
The core legal basis for China's patent term compensation system is Article 42 of the Patent Law. This article adds two new provisions: first, if unreasonable delays by the China National Intellectual Property Administration (CNIPA) in substantive examination result in a patent grant delay exceeding four years, compensation may be requested; second, to compensate for the time occupied by the review and approval of new drug marketing, for invention patents related to new drugs that have obtained marketing approval in China, CNIPA shall, upon the request of the patentee, grant a patent term extension. The extension period shall not exceed five years, and the total effective patent term after the new drug is approved for marketing shall not exceed 14 years.
This system draws on the experience of the U.S. Hatch-Waxman Act and the systems of Japan, South Korea, and other countries, but has Chinese characteristics. For example, the extension applies only to "new drugs," not to generic drugs or improved new drugs of already marketed drugs (such as new dosage forms or new indications). Foreign companies should note that China's PTE system applies only to "invention patents," not to utility model or design patents. In addition, the request for extension must be filed within three months after the patent grant announcement and after the new drug obtains marketing approval; both conditions are indispensable.
For foreign pharmaceutical companies, understanding the definition of "new drug" is crucial. According to the Drug Administration Law and the classification of the National Medical Products Administration (NMPA), new drugs generally refer to "innovative drugs" and "improved new drugs," but the PTE system currently covers only "innovative drugs" (i.e., Class 1 new drugs). Whether Class 2 improved new drugs (such as new dosage forms or new combinations) are eligible is controversial in practice, and it is recommended to consult professional institutions such as WeRights before filing.
### Applicable Conditions and Qualification Requirements
To successfully obtain a patent term extension, foreign pharmaceutical companies must meet all of the following conditions:
1. **Patent Type**: It must be an invention patent, and the patent must relate to a new drug or its preparation method or use. Compound patents, formulation patents, and use patents are all eligible, but they must be directly related to the marketed new drug.
2. **Marketing Approval**: The new drug must have obtained marketing approval from NMPA in China. Approval only in other countries without marketing in China does not satisfy the condition.
3. **First Marketing**: The extension applies only to new drugs that have obtained marketing approval for the first time in China. If the drug has already been marketed in other countries but China is the first approval site, it is still eligible. However, if a generic version of the drug has already been marketed in China (e.g., through patent challenges), eligibility may be lost.
4. **Request Deadline**: The patentee must submit a written request to CNIPA within three months from the date of the patent grant announcement and after the new drug marketing approval is granted. Failure to do so is deemed a waiver.
5. **No Abuse of Rights**: If the patentee has engaged in abuse of the patent system (e.g., maliciously delaying examination), CNIPA may reject the request.
The following table summarizes the main differences between the PTE system and ordinary patent terms:
| Item | Ordinary Patent Term | Patent Term Extension (PTE) |
|------|---------------------|-----------------------------|
| Starting Point | Patent filing date | Starts after the original patent term expires |
| Maximum Total Term | 20 years | No more than 14 years from the date of marketing approval |
| Extension Cap | Not applicable | 5 years |
| Eligible Subject Matter | All invention patents | Only invention patents related to new drugs |
| Request Deadline | Not applicable | Within 3 months after patent grant + after new drug approval |
Foreign companies should pay special attention: PTE compensates only for "marketing approval delays," not for "patent examination delays." The latter has a separate "examination delay compensation" system (i.e., for unreasonable delays by CNIPA exceeding four years), and the two cannot be stacked. However, if the same patent meets both conditions, the better compensation can be calculated separately and applied.
### Calculation Method for the Extension Period
The calculation of the extension period is the most practical concern for foreign companies. According to the Implementing Regulations of the Patent Law and related guidelines, the calculation formula is:
**Extension Days = (Days from the new drug marketing application (NDA) submission date to the new drug approval date) - (Days of approval period before the patent grant date) - (Days of delay attributable to the patentee)**
The specific steps are as follows:
1. **Determine the Base Period**: From the date NMPA accepts the new drug marketing application to the date of marketing approval (i.e., the "administrative approval period"). For example, if the NDA is submitted on January 1, 2022, and approved on June 1, 2024, the base period is 882 days.
2. **Deduct Pre-Grant Time**: The time from the NDA submission date to the patent grant date is not included in the compensation. Assuming the patent is granted six months after the NDA submission (July 1, 2022), this six-month period (approximately 183 days) must be deducted from the base period.
3. **Deduct Applicant Delays**: If the company voluntarily suspends the review, supplements materials, or causes delays due to its own reasons during the approval process, these days must also be deducted. For example, if the company requests a 60-day suspension of review due to clinical trial data issues, these 60 days are not compensated.
4. **Convert to Years**: The final number of days is divided by 365, rounded to two decimal places, but the extension cap is five years. At the same time, the total effective patent term after new drug approval (remaining original patent term + extension period) must not exceed 14 years.
Example: Assume a foreign pharmaceutical company's compound patent was filed on January 1, 2018, and granted on January 1, 2022. The NDA for the new drug was submitted on January 1, 2021, and approved on January 1, 2023. The original patent expires on January 1, 2038. The calculation is as follows:
- Administrative approval period: January 1, 2021, to January 1, 2023 = 730 days
- Pre-grant time: January 1, 2021, to January 1, 2022 = 365 days
- After deduction: 730 - 365 = 365 days (approximately 1 year)
- Total term after extension: Original patent remaining 15 years (2038-2023) + 1 year = 16 years, but the cap is 14 years, so the actual patent expires on January 1, 2037 (i.e., 2023 + 14 years).
Note: If the base period after deduction is less than 0 years, no extension is granted.
### Application Procedure and Key Milestones
Foreign pharmaceutical companies should follow the steps below to avoid loss of rights due to procedural defects:
1. **Internal Assessment**: Within 10 days after the new drug is approved, assess whether the patent meets the PTE conditions. Key checks include: whether the patent is directly related to the approved new drug, whether it is within three months after grant, and whether there are any prior marketing records. It is recommended to engage a professional institution (such as WeRights) for due diligence.
2. **Prepare Documents**: This includes a copy of the patent certificate, NMPA new drug approval certificate (including acceptance date and approval date), a statement of the relationship between the patent and the drug, and the applicant's identity certificate (foreign companies need to provide notarized translations). If the patentee and the marketing authorization holder are different, a licensing agreement or proof of ownership must be submitted.
3. **Submit Request**: Submit the "Request for Patent Term Extension" and attachments to CNIPA. This can be done through the electronic filing system or in person. CNIPA will issue an acceptance notice or a correction notice within 30 days of receipt.
4. **Examination and Decision**: CNIPA completes the examination within six months, primarily verifying the accuracy of the calculation and whether the conditions are met. If no objections are raised, a "Decision on Patent Term Extension" is issued and published; if rejected, an administrative reconsideration or administrative litigation may be filed.
5. **Publication and Implementation**: Once the extension takes effect, the patent protection period is automatically extended. Companies can use this to assert rights against generic drug manufacturers. Note: During the extension period, the scope of patent protection is limited to the approved new drug and its indications and does not extend to other uses.
Key Milestone Checklist:
- Patent Grant Date: Starts the three-month request period
- New Drug Approval Date: Must occur before the request
- Request Submission Date: No later than three months after patent grant
- CNIPA Decision Date: Usually within six months after the request
### Risk Control and Strategic Recommendations
Foreign pharmaceutical companies should be aware of the following risks when implementing the PTE system in China:
1. **Disputes over the Relationship Between Patent and Drug**: CNIPA strictly reviews "direct relevance." If the patent involves only intermediates or non-critical processes, it may be rejected. It is recommended to draft claims directly corresponding to the new drug at the patent application stage, such as "a pharmaceutical composition comprising compound X" rather than "a method for preparing compound X."
2. **Coordination of Multiple Patents**: The same new drug may involve multiple patents (compound, formulation, use). PTE can only be applied to one of these patents. Companies should choose the patent with the longest remaining term or the highest commercial value. For example, compound patents typically have shorter remaining terms but may result in a longer total term after extension; formulation patents have longer remaining terms, but the extension cap may limit the total term.
3. **Generic Drug Challenges**: During the extension period, generic drug companies may file patent challenges under the "Early Resolution Mechanism for Drug Patent Disputes." If the challenge succeeds, the PTE may be declared invalid. Therefore, companies need to monitor the registration status of generic drugs simultaneously and initiate judicial proceedings when necessary.
4. **International Coordination**: China's PTE system differs from the U.S. PTE and Japan's PTE. For example, the U.S. PTE compensates for both the marketing approval period and patent examination delays, while China compensates only for the marketing approval period. Companies should treat China's PTE as an independent variable in global patent portfolio management to avoid market exclusivity gaps due to calculation errors.
5. **Professional Support**: Given the legal complexity, it is strongly recommended that foreign companies engage Chinese patent agencies (such as WeRights) to handle PTE applications. WeRights can provide one-stop services including patent analysis, document preparation, examination communication, and assistance with subsequent disputes.
Finally, foreign companies should establish an internal early warning mechanism: assess the China market pathway early in new drug R&D, communicate with NMPA on the approval timeline before NDA submission, and initiate PTE preparations immediately after patent grant. Through proactive management, the PTE system can be transformed from a "compensation" into a "strategic asset," maximizing returns in the Chinese market.
(Information in this article is current as of 2024. Specific legal application is subject to the latest regulations and CNIPA guidelines. For further consultation, contact the professional team via Telegram @token_1_com.)
๐ฉ Need Help with Your IP Registration?
Contact us on Telegram for a free consultation. We respond within 24 hours.
๐ Message @token_1_com